Buddy Lyons
Value, long/short equity, contrarian, growth

Tesaro Offers Excellent Risk-Reward: Market Overreacted To Weaker-Than-Expected Data

Tesaro (NASDAQ:TSRO) tumbled almost 25% on Monday as investors question its ability to differentiate its drug for chemotherapy induced nausea and vomiting (CINV) from existing NK-1 antagonists after missing secondary endpoints in two phase III trials. Rolapitant achieved the primary endpoint of complete response (CR) in the delayed period (24-120 hours) following initiation of chemotherapy in both a highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). The missed secondary endpoints were overall complete response (0-120 hours) and acute complete response (0-24 hours). We believe the stock price movement is an overreaction and presents a buying opportunity for speculative, patient investors with over 100% potential upside versus 26% potential downside over the next 24 months.

Our investment premise...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details